Evaluation Study of Traditional Chinese Medicine Syndrome Differentiation Therapy on the Quality of Life and Efficacy Satisfaction in Elderly Community-acquired Pneumonia Patients after Discharge

doi:10.12114/j.issn.1007-9572.2023.0446

Chinese General Practice ›› 2024, Vol. 27 ›› Issue (08): 1001-1007.DOI: 10.12114/j.issn.1007-9572.2023.0446

Special Issue: 老年问题最新文章合辑；中医最新文章合辑；呼吸疾病文章合辑；老年人群健康最新文章合辑

• Original Research • Previous Articles Next Articles

Evaluation Study of Traditional Chinese Medicine Syndrome Differentiation Therapy on the Quality of Life and Efficacy Satisfaction in Elderly Community-acquired Pneumonia Patients after Discharge

1. The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
2. Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province & Education Ministry of P-R.China/Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China

Received:2023-08-20 Revised:2023-11-01 Published:2024-03-15 Online:2023-11-29
Contact: LI Jiansheng

中医辨证治疗方案对老年社区获得性肺炎出院后患者生存质量和疗效满意度的评价研究

1．450000　河南省郑州市，河南中医药大学第一附属医院
2．450046　河南省郑州市，河南中医药大学呼吸疾病中医药防治省部共建协同创新中心　河南省中医药防治呼吸病重点实验室

通讯作者: 李建生
作者简介:
作者贡献：李建生提出老年肺炎患者出院后病机观点、证候类型及有效方药，顶层设计整体研究方案；王明航负责研究方案的论证完善，研究过程的实施和质量控制，伦理审查、项目启动、病例招募分中心监查等；韩伟红、毕丽婵负责临床研究数据的收集、清洗和统计学分析等；韩伟红、杨江负责论文起草；李建生负责最终版本修订，对论文负责。
基金资助:
河南省科技攻关项目(232102310472); 河南省疫情防控应急科研项目(221111312000); 河南省中医药科学研究专项(2022ZY1047); 青年岐黄学者(国中医药人教发〔2020〕7号); 中原基础领军人才(ZYYCYU202012124); 河南省高校科技创新团队(23IRTSTHN027)

Abstract

Abstract:

Background

Community-acquired pneumonia (CAP) is one of the common infectious diseases, especially in elderly patients, with atypical clinical symptoms, which is susceptibility to serious complications, lacks effective treatment measures, and often has a poor prognosis.

Objective

To investigate the effect of traditional Chinese medicine (TCM) syndrome differentiation therapy on the quality of life and efficacy satisfaction of elderly patients with CAP discharged from hospital (within 1 week) .

Methods

This study was designed as a multicentre, randomized double-blind placebo clinical study. Elderly CAP post-discharge patients admitted to the respiratory departments of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Chest Hospital, Henan People's Hospital, Zhengzhou Hospital of Traditional Chinese Medicine and Zhengzhou People's Hospital from April 2018 to January 2020 were selected as the study subjects and divided into the experimental group and control group by using a central randomized group enrolment model. The patients in the experimental group were treated with corresponding TCM granules based on syndrome differentiation, and the lung-tonifying spleen-invigorating phlegm-reducing formula was given for syndrome of phlegm-dampness due to qi deficiency, and the qi-supplementing yin-nourishing lung-clearing formula was given for qi and yin deficiency and phlegm-heat syndrome. The control group was given a placebo with the same appearance, weight, color, and smell as the Chinese medicine granules. The treatment course was 2 months, and the follow-up was up to 6 months. The quality of life evaluated by the Chinese version of the Quality of Life Rating Scale (SF-36) and efficacy satisfaction evaluated by the Efficacy Satisfaction Questionnaire for CAP (ESQ-CAP) were compared between the two groups before the treatment, 1 month after the treatment, 2 months after the treatment, 3 months after the follow-up, and 6 months after the follow-up.

Results

Among the 120 subjects included, 8 were dislodged and 112 were finally included that met the protocol set, including 54 cases in the experimental group and 58 cases in the control group. There was no significant difference in gender, age, time after discharge, TCM syndrome differentiation, CUBR-65 score, and underlying diseases between the two groups before treatment (P>0.05) . The main effects of the group were significant on SF-36 physiological function domain score (F_group=5.057, P_group=0.027) , general health domain score (F_group=7.286, P_group=0.008) , and role limitations due to emotional problems domain score (F_group=6.858, P_group=0.010) . Comparison between the two groups showed that SF-36 physical function domain score of the experimental group was higher than that of the control group at 2 months of treatment, 3 months of follow-up, and 6 months of follow-up (P<0.05) ; SF-36 general health status domain and role limitations due to emotional problems domain scores of the experimental group were higher than those of the control group at 1 and 2 months of treatment, 3 and 6 months of follow-up (P<0.05) ; the SF-36 domain score for role limitations due to mental health was higher than that of the control group (P<0.05) at 3 and 6 months of follow-up. The main effect of group on ESQ-CAP daily living and ability domain score (F_group=16.218, P_group<0.001) , convenience domain score (F_group=25.013, P_group<0.001) , and ESQ-CAP total score (F_group=13.843, P_group<0.001) was significant. The ESQ-CAP daily living and ability domain scores were higher in the experimental group than the control group at 2 months of treatment, 3 and 6 months of follow-up (P<0.05) . At 1 and 2 months of treatment and 3 and 6 months of follow-up, ESQ-CAP convenience domain score and ESQ-CAP total score were higher in the experimental group than in the control group (P<0.05) . At 3 months of follow-up, the ESQ-CAP overall efficacy domain score was higher in the experimental group than the control group (P<0.05) .

Conclusion

The TCM syndrome differentiation therapy scheme can improve the quality of life and efficacy satisfaction of elderly patients with CAP after discharge.

Key words: Pneumonia, Community-acquired pneumonia, Treatment based on syndrome differentiation, Quality of life, Efficacy satisfaction

摘要：

背景

社区获得性肺炎（CAP）为常见的感染性疾病之一，尤其在老年患者中，其临床症状不典型，易出现严重并发症，缺乏有效的治疗措施，常预后不良。

目的

探究中医辨证治疗方案对老年CAP出院（1周内）患者的生存质量及其疗效满意度情况。

方法

本研究为多中心、随机双盲安慰剂临床研究。选取河南中医药大学第一附属医院、河南省胸科医院、河南省人民医院、郑州市中医院、郑州人民医院5家医院呼吸科2018年4月—2020年1月病房收治的老年CAP出院后患者为研究对象，采用中央随机入组模式将患者分为试验组和对照组。试验组患者经中医辨证后给予相应中药颗粒剂进行治疗，气虚痰湿证给予补肺健脾化痰方，气阴虚痰热证给予益气养阴清肺方。对照组则给予与中药颗粒外观、重量、颜色、气味基本一致的安慰剂。治疗疗程为2个月，随访至治疗开始后6个月。比较两组患者治疗前、治疗1个月、治疗2个月、随访3个月、随访6个月的生存质量[采用中文版生存质量评分量表（SF-36）评价]和疗效满意度[采用肺炎患者疗效满意度问卷（ESQ-CAP）评价]。

结果

纳入120例患者中，脱落8例，最终纳入符合方案集的病例112例，其中试验组54例、对照组58例。治疗前两组性别、年龄、出院后时间、中医辨证分型、CUBR-65评分、基础疾病比较，差异无统计学意义（P>0.05）。组别对SF-36生理机能领域评分（F_组间=5.057，P_组间=0.027）、一般健康状况领域评分（F_组间=7.286，P_组间=0.008）、情感职能领域评分（F_组间=6.858，P_组间=0.010）主效应显著。组间比较：治疗2个月、随访3个月、随访6个月，试验组SF-36生理机能领域评分高于对照组（P<0.05）；治疗1、2个月和随访3、6个月，试验组SF-36一般健康状况领域、情感职能领域评分高于对照组（P<0.05）；随访3、6个月，试验组SF-36精神健康领域评分高于对照组（P<0.05）。组别对ESQ-CAP日常生活与能力领域评分（F_组间=16.218，P_组间<0.001）、方便领域评分（F_组间=25.013，P_组间<0.001）及ESQ-CAP总分（F_组间=13.843，P_组间<0.001）主效应显著。治疗2个月和随访3、6个月，试验组ESQ-CAP日常生活与能力领域评分高于对照组（P<0.05）。治疗1、2个月和随访3、6个月，试验组ESQ-CAP方便领域评分及ESQ-CAP总分高于对照组（P<0.05）。随访3个月，试验组ESQ-CAP总体疗效领域评分高于对照组（P<0.05）。

结论

中医辨证治疗方案对于老年CAP出院后患者的生存质量和疗效满意度具有较好的改善作用。

关键词: 肺炎, 社区获得性肺炎, 辨证治疗方案, 生存质量, 疗效满意度

WANG Minghang,HAN Weihong,BI Lichan, et al. Evaluation Study of Traditional Chinese Medicine Syndrome Differentiation Therapy on the Quality of Life and Efficacy Satisfaction in Elderly Community-acquired Pneumonia Patients after Discharge[J]. Chinese General Practice, 2024, 27(08): 1001-1007. DOI: 10.12114/j.issn.1007-9572.2023.0446.
王明航,韩伟红,毕丽婵等. 中医辨证治疗方案对老年社区获得性肺炎出院后患者生存质量和疗效满意度的评价研究[J]. 中国全科医学, 2024, 27(08): 1001-1007. DOI: 10.12114/j.issn.1007-9572.2023.0446.

Figures/Tables 3

References 17

[1]	CILLÓNIZ C, LIAPIKOU A, MARTIN-LOECHES I，et al. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia[J]. PLoS One，2018,13(7):e0200504. DOI：10.1371/journal.pone.0200504.
[2]	METLAY J P, WATERER G W, LONG A C，et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American thoracic society and infectious diseases society of America[J]. Am J Respir Crit Care Med，2019,200(7):e45-67. DOI：10.1164/rccm.201908-1581ST.
[3]	KRONE C L, VAN DE GROEP K, TRZCIŃSKI K，et al. Immunosenescence and pneumococcal disease：an imbalance in host-pathogen interactions[J]. Lancet Respir Med，2014,2(2):141-153. DOI：10.1016/S2213-2600(13)70165-6.
[4]	CILLÓNIZ C, RODRÍGUEZ-HURTADO D, TORRES A. Characteristics and management of community-acquired pneumonia in the era of global aging[J]. Med Sci，2018,6(2):35. DOI：10.3390/medsci6020035.
[5]	LUNA C M, PALMA I, NIEDERMAN M S，et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia[J]. Ann Am Thorac Soc，2016,13(9):1519-1526. DOI：10.1513/AnnalsATS.201512-848OC.
[6]	中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J]. 中华结核和呼吸杂志，2016,39(4):253-279. DOI：10.3760/cma.j.issn.1001-0939.2016.04.005.
[7]	MANDELL L A, WUNDERINK R G, ANZUETO A，et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis，2007,44(Suppl 2):S27-72. DOI：10.1086/511159.
[8]	CHARLES P G, WOLFE R, WHITBY M，et al. SMART-COP：a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia[J]. Clin Infect Dis，2008,47(3):375-384. DOI：10.1086/589754.
[9]	李建生. 基于疗效优势的中医治疗社区获得性肺炎切入点的思考[J]. 中医学报，2017,32(3):345-347. DOI：10.16368/j.issn.1674-8999.2017.03.089.
[10]	李建生，王明航，毕丽婵，等. 中医辨证治疗方案降低老年社区获得性肺炎患者再住院率的疗效评价[J]. 中华中医药杂志，2022,37(2):1171-1178.
[11]	郑筱萸. 中药新药临床研究指导原则：试行[M]. 北京：中国医药科技出版社，2002.
[12]	李建生，王至婉，李素云. 社区获得性肺炎中医证候诊断标准（2011版）[J]. 中医杂志，2011,52(24):2158-2159. DOI：10.13288/j.11-2166/r.2011.24.030.
[13]	WARE J E Jr, SHERBOURNE C D. The MOS 36-item short-form health survey （SF-36）. I. Conceptual framework and item selection[J]. Med Care，1992,30(6):473-483.
[14]	华俏丽，刘慧玲，徐晓花，等. 新型冠状病毒感染康复者极早期认知功能障碍及影响因素研究[J]. 中国全科医学，2023,26(10):1234-1240. DOI：10.12114/j.issn.1007-9572.2022.0870.
[15]	李建生，王明航，余学庆，等. 社区获得性肺炎疗效测评工具的研制与评价[J]. 中医学报，2016,31(11):1654-1661. DOI：10.16368/j.issn.1674-8999.2016.11.465.
[16]	丘金彩，许军，冯丽仪，等. 应用SF-36量表评价社会人口学因素对中国华南地区公务员生存质量的影响研究[J]. 中国全科医学，2012,15(13):1454-1459,1463. DOI：10.3969/j.issn.1007-9572.2012.13.011.
[17]	XU Z J, CHEN J, XU R J. A randomised controlled study：efficacy of ICU nursing risk management combined with the cluster nursing model and its effect on quality of life and inflammatory factor levels of patients with acute respiratory distress syndrome and ventilator-associated pneumonia[J]. Ann Palliat Med，2021,10(7):7587-7595. DOI：10.21037/apm-21-1192.

组别	例数	性别（男/女）	年龄（岁）	出院后时间（d）	中医辨证[例（%）]		CUBR-65评分[例（%）]		基础疾病[例（%）]
组别	例数	性别（男/女）	年龄（岁）	出院后时间（d）	气虚痰湿证	气阴虚痰热证	1分	2分	有	无
对照组	58	23/35	70.4±6.5	1.36±0.69	27（46.6）	31（53.4）	50（86.2）	8（13.8）	36（62.1）	22（37.9）
试验组	54	22/32	70.9±7.0	1.20±0.44	25（46.3）	29（53.7）	52（96.3）	2（3.7）	38（70.4）	16（29.6）
χ²（t）值		0.014	-0.268^a	-1.489^a	0.001		—		0.860
P值		0.907	0.789	0.137	0.978		0.096		0.354

组别	例数	性别（男/女）	年龄（岁）	出院后时间（d）	中医辨证[例（%）]		CUBR-65评分[例（%）]		基础疾病[例（%）]
组别	例数	性别（男/女）	年龄（岁）	出院后时间（d）	气虚痰湿证	气阴虚痰热证	1分	2分	有	无
对照组	58	23/35	70.4±6.5	1.36±0.69	27（46.6）	31（53.4）	50（86.2）	8（13.8）	36（62.1）	22（37.9）
试验组	54	22/32	70.9±7.0	1.20±0.44	25（46.3）	29（53.7）	52（96.3）	2（3.7）	38（70.4）	16（29.6）
χ²（t）值		0.014	-0.268^a	-1.489^a	0.001		—		0.860
P值		0.907	0.789	0.137	0.978		0.096		0.354

组别	例数	生理机能领域					生理职能领域
组别	例数	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	58	70.60±15.98	71.12±16.99	72.64±15.34	74.22±14.56	74.74±14.70	35.78±34.76	48.90±37.46	70.26±35.19	74.06±35.60	76.29±33.91
试验组	54	70.55±18.93	76.02±15.85	78.76±14.39^a	81.76±12.48^a	82.71±12.50^a	35.19±42.48	59.10±38.39	78.70±30.87	79.55±32.56	82.95±30.63
F值		F_时间=5.290，F_组别=5.057，F_交互=1.543					F_时间=22.631，F_组别=2.188，F_交互=0.462
P值		P_时间=0.001，P_组别=0.027，P_交互=0.195					P_时间<0.001，P_组别=0.142，P_交互=0.763
组别	躯体疼痛领域					一般健康状况领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	76.22±22.97	77.29±21.97	78.34±22.09	80.33±21.40	81.07±21.36	35.81±23.07	36.17±21.06	40.67±21.79	41.79±24.82	43.25±25.74
试验组	78.50±22.90	83.30±19.91	84.35±18.95	85.03±15.45	86.76±16.21	36.99±20.57	46.28±20.76^a	49.89±21.31^a	55.07±23.64^a	57.20±23.60^a
F值	F_时间=1.611，F_组别=2.736，F_交互=0.337					F_时间=7.065，F_组别=7.286，F_交互=1.945
P值	P_时间=0.177，P_组别=0.101，P_交互=0.853					P_时间<0.001，P_组别=0.008，P_交互=0.108
组别	精力领域					社会功能领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	63.53±13.31	63.97±13.10	65.69±13.91	66.72±16.05	67.41±16.63	68.10±20.03	71.98±19.63	76.94±21.18	81.90±19.75	84.48±15.93
试验组	63.06±18.29	67.22±12.00	69.91±13.48	71.60±12.88	72.41±13.13	69.91±18.09	78.47±17.24	84.03±15.81	84.95±19.33	88.75±13.59
F值	F_时间=5.186，F_组别=2.173，F_交互=0.979					F_时间=16.818，F_组别=3.630，F_交互=1.007
P值	P_时间=0.001，P_组别=0.143，P_交互=0.422					P_时间<0.001，P_组别=0.059，P_交互=0.407
组别	情感职能领域					精神健康领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	56.32±40.08	63.22±44.01	70.11±44.45	71.84±42.72	75.29±36.71	71.10±13.19	71.36±13.66	74.28±12.83	76.37±12.64	77.17±12.56
试验组	56.56±39.70	80.86±31.46^a	88.27±27.59^a	89.51±28.83^a	90.74±25.42^a	72.44±11.65	73.85±12.18	77.70±12.00	81.88±11.41^a	82.20±11.38^a
F值	F_时间=10.675，F_组别=6.858，F_交互=1.203					F_时间=14.263，F_组别=3.118，F_交互=1.149
P值	P_时间<0.001，P_组别=0.010，P_交互=0.314					P_时间<0.001，P_组别=0.080，P_交互=0.338

组别	例数	生理机能领域					生理职能领域
组别	例数	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	58	70.60±15.98	71.12±16.99	72.64±15.34	74.22±14.56	74.74±14.70	35.78±34.76	48.90±37.46	70.26±35.19	74.06±35.60	76.29±33.91
试验组	54	70.55±18.93	76.02±15.85	78.76±14.39^a	81.76±12.48^a	82.71±12.50^a	35.19±42.48	59.10±38.39	78.70±30.87	79.55±32.56	82.95±30.63
F值		F_时间=5.290，F_组别=5.057，F_交互=1.543					F_时间=22.631，F_组别=2.188，F_交互=0.462
P值		P_时间=0.001，P_组别=0.027，P_交互=0.195					P_时间<0.001，P_组别=0.142，P_交互=0.763
组别	躯体疼痛领域					一般健康状况领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	76.22±22.97	77.29±21.97	78.34±22.09	80.33±21.40	81.07±21.36	35.81±23.07	36.17±21.06	40.67±21.79	41.79±24.82	43.25±25.74
试验组	78.50±22.90	83.30±19.91	84.35±18.95	85.03±15.45	86.76±16.21	36.99±20.57	46.28±20.76^a	49.89±21.31^a	55.07±23.64^a	57.20±23.60^a
F值	F_时间=1.611，F_组别=2.736，F_交互=0.337					F_时间=7.065，F_组别=7.286，F_交互=1.945
P值	P_时间=0.177，P_组别=0.101，P_交互=0.853					P_时间<0.001，P_组别=0.008，P_交互=0.108
组别	精力领域					社会功能领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	63.53±13.31	63.97±13.10	65.69±13.91	66.72±16.05	67.41±16.63	68.10±20.03	71.98±19.63	76.94±21.18	81.90±19.75	84.48±15.93
试验组	63.06±18.29	67.22±12.00	69.91±13.48	71.60±12.88	72.41±13.13	69.91±18.09	78.47±17.24	84.03±15.81	84.95±19.33	88.75±13.59
F值	F_时间=5.186，F_组别=2.173，F_交互=0.979					F_时间=16.818，F_组别=3.630，F_交互=1.007
P值	P_时间=0.001，P_组别=0.143，P_交互=0.422					P_时间<0.001，P_组别=0.059，P_交互=0.407
组别	情感职能领域					精神健康领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	56.32±40.08	63.22±44.01	70.11±44.45	71.84±42.72	75.29±36.71	71.10±13.19	71.36±13.66	74.28±12.83	76.37±12.64	77.17±12.56
试验组	56.56±39.70	80.86±31.46^a	88.27±27.59^a	89.51±28.83^a	90.74±25.42^a	72.44±11.65	73.85±12.18	77.70±12.00	81.88±11.41^a	82.20±11.38^a
F值	F_时间=10.675，F_组别=6.858，F_交互=1.203					F_时间=14.263，F_组别=3.118，F_交互=1.149
P值	P_时间<0.001，P_组别=0.010，P_交互=0.314					P_时间<0.001，P_组别=0.080，P_交互=0.338

组别	例数	日常生活与能力领域
组别	例数	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	58	12.50±2.56	12.80±2.30	13.21±2.43	13.34±3.02	13.47±3.06
试验组	54	12.85±2.00	14.22±2.42^a	14.89±2.38^a	15.41±2.18^a	15.74±2.84^a
F值		F_时间=9.002，F_组别=16.218，F_交互=2.337
P值		P_时间<0.001，P_组别<0.001，P_交互=0.060
组别	治疗效果领域					方便领域
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	9.78±1.69	9.71±1.74	9.93±2.25	10.14±2.22	10.24±2.35	6.81±1.05	6.91±1.03	6.95±1.16	7.03±1.21	7.07±1.25
试验组	9.84±1.52	10.22±1.58	10.63±1.72	10.85±1.82	10.91±1.65	6.85±1.20	7.72±1.22^a	7.93±1.06^a	8.04±0.87^a	8.17±1.19^a
F值	F_时间=3.650，F_组别=3.520，F_交互=0.861					F_时间=6.932，F_组别=25.013，F_交互=3.212
P值	P_时间=0.008，P_组别=0.063，P_交互=0.490					P_时间<0.001，P_组别<0.001，P_交互=0.016
组别	总体疗效领域					ESQ-CAP总分
组别	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月	治疗前	治疗1个月	治疗2个月	随访3个月	随访6个月
对照组	2.93±0.81	3.03±0.77	3.22±0.82	3.24±0.80	3.40±0.79	32.02±4.84	32.45±4.73	33.31±5.97	33.76±6.58	34.17±6.74
试验组	2.98±0.69	3.15±0.68	3.30±0.60	3.54±0.72^a	3.61±0.66	32.52±3.63	35.32±4.34^a	36.74±4.12^a	37.83±4.36^a	38.43±5.21^a
F值	F_时间=10.717，F_组别=1.787，F_交互=1.120					F_时间=10.906，F_组别=13.843，F_交互=3.080
P值	P_时间<0.001，P_组别=0.184，P_交互=0.351					P_时间<0.001，P_组别=0.001，P_交互=0.019

Evaluation Study of Traditional Chinese Medicine Syndrome Differentiation Therapy on the Quality of Life and Efficacy Satisfaction in Elderly Community-acquired Pneumonia Patients after Discharge

中医辨证治疗方案对老年社区获得性肺炎出院后患者生存质量和疗效满意度的评价研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 17

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655.
[2]	WU Ruining, ZHOU Ming, ZHANG Gongzi, LI Jun, XIE Suhang, LIU Yangxiaoxue, ZHANG Jiali, LIU Maomao, HUANG Liping. Study on Fixed and Mobile Exoskeleton Robots in Improving Lower Limb Function and Quality of Life in Stroke Patients: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(17): 2326-2333.
[3]	HU Qi, XU Ning, MA Ximin, HE Jiahui, QIAO Hui. The Health-related Quality of Life of Rural Women in the Southern Mountainous Regions of Ningxia Hui Autonomous Region and Its Impact on the Utilization of Health Services [J]. Chinese General Practice, 2026, 29(08): 988-996.
[4]	JIANG Xuan, CHEN Yinhai, LU Yuanwei, ZHANG Jiali, LIN Congxuan, KE Xiong. Impact of Childhood Adverse Experiences on Health-related Quality of Life in Adulthood: a Mediating Role of the Number of Chronic Diseases [J]. Chinese General Practice, 2026, 29(07): 893-899.
[5]	MIN Yeping, XUE Yao, FENG Tongbao, ZHANG He, LIU Fujing. Effect of Blood Pressure Response Index on Acute Kidney Injury in Elderly Patients with Severe Pneumonia Shock [J]. Chinese General Practice, 2026, 29(02): 207-212.
[6]	REN Panpan, JIA Changli, JIA Jingjing, XU Jinglin, CHEN Mengyao, ZHANG Xiang. The Impact of Livelihood Capitals on the Quality of Life of Rural Older Adults: a Study Based on Different Chronic Disease Conditions [J]. Chinese General Practice, 2026, 29(01): 129-136.
[7]	WANG Lizhu, LI Sihan, WANG Xinyi, MAO Sunxi, QIU Yang, WANG Zhonghua. Pathway Analysis of the Impact of Diabetes Knowledge and Self-efficacy on Self-management and Quality of Survival among Rural Patients with Type 2 Diabetes Mellitus Based on ITHBC Modeling [J]. Chinese General Practice, 2025, 28(34): 4351-4358.
[8]	SU Qing, XU Yao, LI Yihang, WANG Liyan, CAI Yefeng, NI Xiaojia. Quality Evaluation of Methodology on the Changes in Traditional Chinese Medicine Syndromes of Stroke and Risk Population [J]. Chinese General Practice, 2025, 28(29): 3694-3702.
[9]	HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258.
[10]	WU Yue, WANG Xuetong, KE Bilian. Evaluation of Vision-related Quality of Life in Myopic Macular Degeneration Patients with Low Vision and Associated Factors [J]. Chinese General Practice, 2025, 28(23): 2908-2914.
[11]	WEN Min, ZHOU Yongling, LIU Jingjing, JIANG Keqing, LIU Juan, ZHU Xiaodan. The Effect and Mechanism of Compensatory Cognitive Training Based on mHealth APP on Stable Schizophrenia Patients [J]. Chinese General Practice, 2025, 28(22): 2819-2825.
[12]	YANG Jiang, LI Jiansheng, CHEN Yaolong, LIU Huiguo, WANG Jianxin, YU Jiajie, LI Huiru, XIAO Qionghua, XIE Yang, LI Suyun, WANG Minghang. Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines (2025 Edition) [J]. Chinese General Practice, 2025, 28(20): 2464-2480.
[13]	LI Ruitong, YUE Yuchuan, GU Xujie, XIONG Lingling. Risk Prediction Models for Refractory Mycoplasma Pneumoniae Pneumonia in Children: a Systematic Review [J]. Chinese General Practice, 2025, 28(09): 1105-1114.
[14]	FAN Jianing, CHEN Jieting, WANG Ziqi, FAN Jinhe, JING Mingxia. Analysis of the Development Trajectory of Health-related Quality of Life in Middle-aged and Elderly Patients with Cardiometabolic Diseases and the Influencing Factors [J]. Chinese General Practice, 2025, 28(08): 923-932.
[15]	YAO Dingye, LUO Guiping, SUN Junsheng, REN Jingjing. Diagnosis and Treatment of Halitosis: a General Practice Perspective [J]. Chinese General Practice, 2025, 28(07): 900-904.